AI Article Synopsis
- A 60-year-old woman with metastatic rectal cancer underwent surgery and started a chemotherapy regimen that included bevacizumab.
- After 3 cycles, she developed difficulty swallowing due to a large ulcer in her esophagus, which was suspected to be caused by the bevacizumab.
- Following cessation of bevacizumab and treatment with pantoprazole, her ulcer improved, marking a rare case of an esophageal ulcer linked to this specific cancer treatment.
Article Abstract
A 60-year-old woman with metastatic rectal cancer who after surgical resection of the primary and creation of a palliative ileostomy in May 2006, was started on a regimen of bevacizumab, irinotecan, 5-fluouracil and leucovorin. After 3 cycles, she presented with solid food dysphagia. An endoscopy showed a large, deep ulcer in the lower third of the esophagus. We assumed that it was related to bevacizumab treatment. Bevacizumab was stopped and she was started on pantoprazole. Over the ensuing months, the ulcer improved notably. To the best of our knowledge, an esophageal ulcer associated with bevacizumab treatment has not been reported. This is likely the precursor lesion to a gastrointestinal tract perforation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10637-009-9246-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!